[口腔鳞状细胞癌患者血清中可溶性主要组织相容性复合体I类相关链A]

[Soluble major histocompatibility complex class I-related chain A in sera of patients with oral squamous cell carcinoma].

作者信息

Li Chao, Shi Fangqiong, Yang Dan, Wang Jie, Jian Xinchun, Jiang Canhua

机构信息

Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Changsha,China.

出版信息

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012 Feb;37(2):168-72. doi: 10.3969/j.issn.1672-7347.2012.02.010.

DOI:10.3969/j.issn.1672-7347.2012.02.010

PMID:22561434

Abstract

OBJECTIVE

To examine the expression of soluble major histocompatibility complex class I-related chain A (sMICA) in the serum in patients with oral squamous cell carcinoma (OSCC) and to explore its clinicopathological significance.

METHODS

Seventy-eight OSCC patients were selected as an experiment group, and 19 healthy persons as a control group. The sMICA in the serum in the experiment group and the control group was detected by enzyme-linked immunosorbent assay.

RESULTS

The detection rate of sMICA in the serum in the experiment group was 98.7% (77/78), with the 95% confidence interval 74.30-93.95 pg/mL and the median 82.17 pg/mL, The detection rate in the control group was 94.7% (18/19), with the 95% confidence interval 29.48-50.30 pg/mL and the median 37.54 pg/mL. The sMICA in the serum in the experiment group was higher than that in the control group (P<0.01). There was statistic difference in the serum sMICA in the experiment group among the different clinicopathological parameters such as tumor size, disease stage and regional lymph node status (P<0.05), but no difference was found in gender, age, and tumor differentiation (P>0.05).

CONCLUSION

The sMICA in the serum in the OSCC patients increases, and is related with the tumor size, disease stage and regional lymph node status. Determination of sMICA in the serum may provide useful information to evaluate the immune state of OSCC patients.

摘要

目的

检测口腔鳞状细胞癌（OSCC）患者血清中可溶性主要组织相容性复合体I类相关链A（sMICA）的表达，并探讨其临床病理意义。

方法

选取78例OSCC患者作为实验组，19例健康人作为对照组。采用酶联免疫吸附测定法检测实验组和对照组血清中的sMICA。

结果

实验组血清中sMICA的检出率为98.7%（77/78），95%置信区间为74.30 - 93.95 pg/mL，中位数为82.17 pg/mL；对照组检出率为94.7%（18/19），95%置信区间为29.48 - 50.30 pg/mL，中位数为37.54 pg/mL。实验组血清中的sMICA高于对照组（P<0.01）。实验组血清sMICA在肿瘤大小、疾病分期和区域淋巴结状态等不同临床病理参数之间存在统计学差异（P<0.05），但在性别、年龄和肿瘤分化方面无差异（P>0.05）。